ClinicalTrials.gg
CompletedNCT04140227Updated Mar 4, 2024Results posted

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

A Phase 3 interventional study of NOV03 in Dry Eye Disease (DED), sponsored by Bausch & Lomb Incorporated. Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes — 1 open to participants now, 2 under way, none of them phase 3. perfluorohexyloctane · Dry Eye Syndromes.

Enrollment
6th of 13
256 · median 216
Started
2020
with 2 others
Phase 3
4 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
9 of 13
Bausch & Lomb Incorporated

Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, this one is the 6th largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 2nd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About perfluorohexyloctane

perfluorohexyloctane: first FDA approval 2023 (MIEBO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland Dysfunction).

Further objective is to evaluate the efficacy of perfluorohexyloctane (NOV03) solution during long-term use in subjects with DED associated with MGD.

Read the detailed description

The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland Dysfunction).

Further objective is to evaluate the efficacy of perfluorohexyloctane (NOV03) solution during long-term use in subjects with DED associated with MGD.

03

Conditions studied

  • Dry Eye Disease (DED)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ICF ( Form)
  • Subject-reported history of Drye Eye Disease (DED) in both eyes
  • Ability and willingness to follow instructions, including participation in all study assessments and visits

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, nursing or planning pregnancy
  • Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of , or unwillingness to use acceptable means of
  • slit-lamp findings or abnormal lid anatomy at screening
  • Ocular/peri-ocular
  • History of herpetic keratitis
  • Active ocular allergies or ocular allergies that are expected to be active during the study
  • Ongoing ocular or systemic infection
  • Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study
  • Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period
  • Presence of uncontrolled systemic diseases
  • Presence of known allergy and/or sensitivity to the study drug or saline components
  • Use of any topical treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    NOV03 4 times daily (QID)

    100% Perfluorohexyloctance solution 4 times daily (QID)

    Drug: NOV03

Interventions

  • DrugNOV03

    100% Perfluorohexyloctane

06

What researchers measure

Primary outcomes

  1. Number of Participants With Ocular and Non-ocular Adverse Events

    Time frame: 12 months

07

Results

Posted Dec 29, 2023

Participant flow

Participant flow — Overall Study
MilestoneNOV03 4 Times Daily (QID)
Started256
Completed208
Not completed48
Withdrew: Withdrawal by subject26
Withdrew: Lost to follow-up8
Withdrew: Adverse event8
Withdrew: Death1
Withdrew: Other3
Withdrew: Protocol violation2

Outcome measures

PrimaryNumber of Participants With Ocular and Non-ocular Adverse Events
Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With Ocular and Non-ocular Adverse Events
ParticipantsNOV03 4 Times Daily (QID)
At Least 1 TEAE Ocular and non-Ocular69
At Least 1 IP-related TEAE Ocular and non-Ocular14
At Least 1 SAE Ocular and non-Ocular1
TEAE that led to Drug Withdrawal9

Adverse events

Collected over AE information was captured during the duration of the study of 1 year. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NOV03 4 Times Daily (QID)1/208 (0.5%)10/208 (4.8%)44/208 (21.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventNOV03 4 Times Daily (QID)
Severe Gastric CancerGastrointestinal disorders1/208
pulmonary embolismRespiratory, thoracic and mediastinal disorders1/208
hypoglcaemiaMetabolism and nutrition disorders1/208
femur fractureInjury, poisoning and procedural complications1/208
radius fractureInjury, poisoning and procedural complications1/208
tibia fractureInjury, poisoning and procedural complications1/208
ulna fractureInjury, poisoning and procedural complications1/208
transient ischaemic attackCardiac disorders1/208
schizophreniaPsychiatric disorders1/208
spinal osteoarthritisMusculoskeletal and connective tissue disorders1/208
Most frequent other events
Showing 10 of 16
Most frequent other events
EventNOV03 4 Times Daily (QID)
COVID-19Infections and infestations6/208
HypertensionVascular disorders4/208
Vitreous detachmentEye disorders4/208
Conjuctivitis allergicEye disorders3/208
Lacrimation increasedEye disorders3/208
Vision blurredEye disorders3/208
HypercholesterolaemiaMetabolism and nutrition disorders3/208
SinusitisInfections and infestations2/208
Urinary Tract InfectionInfections and infestations2/208
Dry eyeEye disorders2/208

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Single-arm Open Label
Mean61.2 ± 13.02
Sex: Female, Male
Sex: Female, Male(Participants)Single-arm Open Label
Female146
Male62
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single-arm Open Label
American Indian or Alaska Native0
Asian29
Native Hawaiian or Other Pacific Islander2
Black or African American43
White133
More than one race0
Unknown or Not Reported1
Type of Eyes
Type of Eyes(Participants)Single-arm Open Label
Right Eye121
Left Eye87
08

Study locations

28 sites
  • Bausch Site 124
    Birmingham, Alabama 35233, United States
  • Bausch Site 125
    Scottsdale, Arizona 85254, United States
  • Bausch Site 110
    Glendale, California 91204, United States
  • Bausch Site 121
    Long Beach, California 90805, United States
  • Bausch Site 102
    Mission Hills, California 91345, United States
  • Bausch Site 101
    Newport Beach, California 92663, United States
  • Bausch Site 116
    Rancho Cordova, California 95670, United States
  • Bausch Site 103
    Torrance, California 90505, United States
  • Bausch Site 123
    Torrance, California 90505, United States
  • Bausch Site 127
    Danbury, Connecticut 06810, United States
  • Bausch Site 129
    Fort Myers, Florida 33901, United States
  • Bausch Site 115
    Jacksonville, Florida 32256, United States
  • Bausch Site 106
    Largo, Florida 33773, United States
  • Bausch Site 117
    Tampa, Florida 33603, United States
  • Bausch Site 108
    Lake Villa, Illinois 60046, United States
  • Bausch Site 112
    Indianapolis, Indiana 46260, United States
  • Bausch Site 119
    Edgewood, Kentucky 41017, United States
  • Bausch Site 126
    Winchester, Massachusetts 01890, United States
  • Bausch Site 113
    Kansas City, Missouri 64111, United States
  • Bausch Site 111
    Saint Louis, Missouri 63131, United States
  • Bausch Site 128
    Slingerlands, New York 12159, United States
  • Bausch Site 114
    Raleigh, North Carolina 27603, United States
  • Bausch Site 122
    Cranberry Township, Pennsylvania 16066, United States
  • Bausch Site 107
    Memphis, Tennessee 38119, United States
  • Bausch Site 109
    Nashville, Tennessee 37205, United States
  • Bausch Site 120
    El Paso, Texas 79902, United States
  • Bausch Site 104
    Lakeway, Texas 78738, United States
  • Bausch Site 118
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jan 2022, 15 months.

Results were first posted in Dec 2023, 1 year 11 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2019
First posted
Oct 25, 2019
StartActual
Sep 24, 2020
Primary completionActual
Jan 5, 2022
CompletionActual
Jan 5, 2022
Results first posted
Dec 29, 2023
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04140227
Responsible party
Sponsor
First posted
Oct 25, 2019
Start date
Sep 24, 2020
Primary completion
Jan 5, 2022
Completion
Jan 5, 2022
Results posted
Dec 29, 2023
Last update
Mar 4, 2024

Study contacts

Johnson Varughese
study director · Bausch Health

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perfluorohexyloctane

Start the discussion